Abstract:Abstract Objectives To evaluate the long term risks of invasive breast cancer and death related to breast cancer after non-screen detected ductal carcinoma in situ. Risks for women in the general population and for women diagnosed with ductal carcinoma in situ via the screening programme were compared. Design Population based cohort study. Setting Data from the National Disease Registration Service. Participants All 27 543 women in England who were diagnosed with ductal carcinoma in situ, outside the NHS breast screening programme, during 1990 to 2018. Main outcome measures Incident invasive breast cancer and death caused by breast cancer. Results By 31 December 2018, 3651 women with non-screen detected ductal carcinoma in situ had developed invasive breast cancer, more than four times higher than expected from national cancer incidence rates (ratio of observed to expected rate was 4.21 (95% conference interval 4.07 to 4.35)). The ratio of observed to expected rate of developing invasive breast cancer remained increased throughout follow-up among women aged <45-70 years. The 25 year cumulative risks of invasive breast cancer by age at diagnosis of ductal carcinoma in situ were 27.3% for <45 years, 25.2% for 45-49 years, 21.7% for 50-59 years, and 20.8% for 60-70 years. 908 women died of breast cancer, almost four times higher than that expected from breast cancer death rates in the general population (ratio of observed to expected rate 3.83 (3.59 to 4.09)). The ratio of observed to expected rate of mortality attributed to breast cancer remained increased throughout follow-up. The 25 year cumulative risks of breast cancer death by age at ductal carcinoma in situ diagnosis were 7.6% for <45 years, 5.8% for 45-49 years, 5.9% for 50-59 years, and 6.2% for 60-70 years. Among women aged 50-64 years, and therefore eligible for breast screening by the NHS, the ratio of observed to expected rate of invasive breast cancer in women with non-screen detected compared with screen detected ductal carcinoma in situ was 1.26 (95% conference interval 1.17 to 1.35), while the ratio for mortality from breast cancer was 1.37 (1.17 to 1.60). Among 22 753 women with unilateral ductal carcinoma in situ undergoing surgery, those who had mastectomy rather than breast conserving surgery had a lower 25 year cumulative rate of ipsilateral invasive breast cancer (mastectomy 8.2% (95% conference interval 7.0% to 9.4%), breast conserving surgery with radiotherapy 19.8% (16.2% to 23.4%), and breast conserving surgery with no radiotherapy recorded 20.6% (18.7% to 22.4%)). However, reductions did not translate into a lower 25 year cumulative rate of deaths attributable to breast cancer (mastectomy 6.5% (4.9% to 10.9%), breast conserving surgery with radiotherapy 8.6% (5.9% to 15.5%), breast conserving surgery with no radiotherapy recorded 7.8% (6.3% to 11.5%)). Conclusions For at least 25 years after their diagnosis, women with non-screen detected ductal carcinoma in situ had higher long term risks of invasive breast cancer and breast cancer death than women in the general population. Additionally, they had higher long term risks than women with screen detected ductal carcinoma in situ. Mastectomy was associated with lower risks of invasive breast cancer than breast conserving surgery, even when accompanied by radiotherapy. However, risks of breast cancer death appeared similar for mastectomy, breast conserving surgery with radiotherapy, and breast conserving surgery with no radiotherapy recorded.

Death from Ductal Carcinoma in Situ is Very Low Except in Young and Black Women, US Data Show.

Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study

Risk Factors for Lymph Node Metastasis and the Impact of Adjuvant Chemotherapy on Ductal Carcinoma in Situ with Microinvasion: a Population-Based Study.

Predictors for local invasive recurrence of ductal carcinoma in situ of the breast: a meta-analysis.

Racial disparities in disease‐specific mortality and surgical management of patients with ductal carcinoma in situ with microinvasion

Ductal carcinoma in situ and cause-specific mortality among younger and older postmenopausal women: the Women's Health Initiative

Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ from 1990 to 2018 in England: population based cohort study

Outcomes from low-risk ductal carcinoma in situ: a systematic review and meta-analysis

Analysis of risk factors associated with survival in human epidermal growth factor receptor 2-positive ductal carcinoma in situ using Korean Breast Cancer Society Database

Characteristics, prognosis, risk factors, and management of recently diagnosed ductal carcinoma in situ with microinvasion

Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ: observational cohort study

Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment

Abstract C061: Disparities in second breast cancers among women with ductal carcinoma in situ

Ductal Carcinoma in Situ Has Comparable Prognosis but Different Risk Factors with Ductal Carcinoma in Situ with Micro Invasion

A single-center prognotic analysis of breast ductal carcinoma in situ

Survival outcomes after omission of surgery for ductal carcinoma in situ

Treatment Trends and Prognosis of Breast Ductal Carcinoma in Situ: a Single Center Analysis

The Role of Residential Segregation in Treatment and Outcomes of Ductal Carcinoma in Situ of the Breast

The Oncologic Safety of Breast-Conserving Surgery for Breast Ductal Carcinoma in Situ

Effect of Radiotherapy on Survival of Women with Locally Excised Ductal Carcinoma in Situ of the Breast: a Surveillance, Epidemiology, and End Results Population-Based Analysis.

Abstract IA002: DCIS: Pathological heterogeneity and prognosis definition